[Gene therapy in diabetic foot].
In gene therapy nucleic acids are used for therapy. There are three different concepts in gene therapy for chronic wounds. (1) Synthesis of human recombinant growth factors by gene therapy techniques, (2) Ex-vivo transfection of cell cultures (fibroblasts, keratinocytes) with growth factor DNA and subsequent transplantation of transfected cells on chronic wounds. (3) In-vivo transfection with growth factor DNA, e.g., gene gun, liposomes, viral vector. Clinical studies on gene therapy for diabetic foot ulcers are only available for the local application of human recombinant PDGF-BB growth factor. Meta-analysis shows there is a low but significant effect of PDGF-BB on neuropathic diabetic ulcers, leading to an increase of healing by 10-15% within 20 weeks of treatment.
Schäffer
M
M
Chirurgische Universitätsklinik, Hoppe-Seyler-Strasse 3, 72076 Tübingen.
Coerper
S
S
Becker
H D
HD
D000818:Animals; D000077214:Becaplermin; D017719:Diabetic Foot / Q000628:therapy*; D015316:Genetic Therapy; D006133:Growth Substances / Q000235:genetics; D006801:Humans; D010982:Platelet-Derived Growth Factor / Q000235:genetics; D020574:Proto-Oncogene Proteins c-sis; D014162:Transfection; D016896:Treatment Outcome
D006133:Growth Substances; D010982:Platelet-Derived Growth Factor; D020574:Proto-Oncogene Proteins c-sis; D000077214:Becaplermin